Close Menu

NEW YORK (GenomeWeb) – Nuclea Biotechnologies Founder and former CEO Patrick Muraca is attempting to buy the bankrupt company's assets for $330,000 after they failed to sell at auction in January.

Don Beskrone, Nuclea's Chapter 7 trustee, filed a motion in US Bankruptcy Court for the District of Delaware on March 6 requesting that the court approve the sale of Nuclea's assets to NanoMolecularDx (NMDX), the company Muraca founded as a spinoff from Nuclea in 2015 upon being replaced as Nuclea's President and CEO by Donald Pogorzelski, a former president of Genzyme Diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.